BCSS

:   breast cancer‐specific survival

CAFs

:   cancer‐associated fibroblasts

CI

:   confidence interval

ER

:   estrogen receptor

H&E

:   hematoxylin and eosin

HER2

:   human epidermal growth factor 2

HR

:   hazard ratio

NST

:   no special type

OS

:   overall survival

PR

:   progesterone receptor

RFS

:   recurrence‐free survival

TSR

:   tumor--stroma ratio

Introduction {#ijc32857-sec-0001}
============

Breast cancer mortality rates are declining in most European countries due to early detection and improved treatment options.[1](#ijc32857-bib-0001){ref-type="ref"} Optimizing risk stratification to prevent undertreatment and overtreatment by personalizing therapy is thereby essential.

In the last decade, the interplay of tumor cells and its microenvironment has gained increased interest. The tumor microenvironment, also known as tumor‐associated stroma, consists of immune cells, fibroblasts, pericytes and endothelial cells in an extracellular matrix. The tumor microenvironment plays an active role in creating an environment that favors the tumor cells; increased motility of cells, suppression of the immune response, remodeling of the extracellular matrix and angiogenesis.[2](#ijc32857-bib-0002){ref-type="ref"}, [3](#ijc32857-bib-0003){ref-type="ref"}, [4](#ijc32857-bib-0004){ref-type="ref"}, [5](#ijc32857-bib-0005){ref-type="ref"}, [6](#ijc32857-bib-0006){ref-type="ref"}

A promising prognostic parameter based on the tumor‐associated stroma is the tumor--stroma ratio (TSR). The TSR reflects the amount of tumor--stroma to the cancer cells, which is determined on routinely retrieved hematoxylin and eosin (H&E) stained tissue slides used for pathological assessment of surgically removed breast tissue. TSR assessment is easy, quick and without additional costs. Previous research demonstrated the prognostic value of the TSR in different types of invasive solid tumors, including breast cancer.[7](#ijc32857-bib-0007){ref-type="ref"}, [8](#ijc32857-bib-0008){ref-type="ref"}, [9](#ijc32857-bib-0009){ref-type="ref"}, [10](#ijc32857-bib-0010){ref-type="ref"}, [11](#ijc32857-bib-0011){ref-type="ref"}, [12](#ijc32857-bib-0012){ref-type="ref"}, [13](#ijc32857-bib-0013){ref-type="ref"}, [14](#ijc32857-bib-0014){ref-type="ref"}, [15](#ijc32857-bib-0015){ref-type="ref"}, [16](#ijc32857-bib-0016){ref-type="ref"}, [17](#ijc32857-bib-0017){ref-type="ref"}, [18](#ijc32857-bib-0018){ref-type="ref"}, [19](#ijc32857-bib-0019){ref-type="ref"}, [20](#ijc32857-bib-0020){ref-type="ref"}, [21](#ijc32857-bib-0021){ref-type="ref"}, [22](#ijc32857-bib-0022){ref-type="ref"}, [23](#ijc32857-bib-0023){ref-type="ref"}, [24](#ijc32857-bib-0024){ref-type="ref"}, [25](#ijc32857-bib-0025){ref-type="ref"}, [26](#ijc32857-bib-0026){ref-type="ref"}, [27](#ijc32857-bib-0027){ref-type="ref"}, [28](#ijc32857-bib-0028){ref-type="ref"}, [29](#ijc32857-bib-0029){ref-type="ref"}, [30](#ijc32857-bib-0030){ref-type="ref"}, [31](#ijc32857-bib-0031){ref-type="ref"}, [32](#ijc32857-bib-0032){ref-type="ref"} Most of these studies validated a worse prognosis for patients with stroma‐high tumors.

Breast cancer is a heterogeneous disease, which makes subgroup analysis essential. Kramer *et al*. reviewed literature published on the prognostic value of TSR in the general breast cancer population and different clinically important subgroups.[33](#ijc32857-bib-0033){ref-type="ref"} Here, we set out to validate the effect of the TSR and further expand its utility in the clinically relevant subgroups for breast cancer prognostication. This is an essential step toward prospective validation and clinical implementation, such as the addition of TSR to the frequently used online prediction tool PREDICT.

Materials and Methods {#ijc32857-sec-0002}
=====================

Study population {#ijc32857-sec-0003}
----------------

### *The Nottingham breast cancer series from Nottingham City Hospital (UK)* {#ijc32857-sec-0004}

The study population consists of women of ≤70 years with primary invasive breast cancer without distant metastases, diagnosed and treated primarily with surgery in the Nottingham City Hospital between 1993 and 2002 (*n* = 1809). This cohort was retrospectively assembled. Patients were included if digital H&E slides of the primary breast tumors and follow to up data were available. Exclusion criteria were breast cancer in premedical history and/or neoadjuvant treatment.

### *The ONCOPOOL study from the Netherlands Cancer Institute to Antoni van Leeuwenhoek (the Netherlands)* {#ijc32857-sec-0005}

A total of 737 women treated primarily with surgery for invasive nonmetastatic breast cancer between 1990 and 1999, included in the ONCOPOOL study at The Netherlands Cancer Institute‐Antoni van Leeuwenhoek hospital, were analyzed in our study. The included patients were part of the larger ONCOPOOL database of European primary breast cancer patients. Details on data management and patient selection were described previously.[14](#ijc32857-bib-0014){ref-type="ref"}, [34](#ijc32857-bib-0034){ref-type="ref"} Survival data, estrogen receptor (ER) status, progesterone receptor (PR) status are updated since the previous publication on TSR according to the last publication using the ONCOPOOL study.[14](#ijc32857-bib-0014){ref-type="ref"}, [35](#ijc32857-bib-0035){ref-type="ref"}

All patient data were used in an anonymized manner and data were handled according to national ethical guidelines ("Code for Proper Secondary Use of Human Tissue", Dutch Federation of Medical Scientific Societies"). No additional informed consent was required. The Nottingham Breast Cancer Series was approved by the Nottingham Research Ethics Committee 2 under the title "Development of molecular genetic classification of breast cancer."

Assessment of the TSR {#ijc32857-sec-0006}
---------------------

In the Nottingham Breast Cancer series, the TSR was visually assessed on digital H&E stained slides of the primary breast tumor *via* CaseViewer 2.2 for Windows (3DHISTECH Ltd., Budapest, Hungary), a digital application for the evaluation of microscopic images. The original 4 μm routine H&E stained slides were scanned into high‐resolution (0.19 μm/pixel) digital images at 20× magnification using 3DHistech Panoramic 250 Flash II scanner (3DHISTECH Ltd., Budapest, Hungary). First, the whole tissue slide was visually evaluated for the orientation of the most stromal rich field. Second, the most stromal abundant area was annotated using a circle with an area of 3.1 mm^2^. This microscopic field is comparable with the surface selected with a 10× objective of most light microscopes and corresponds with the magnification used in previously.[36](#ijc32857-bib-0036){ref-type="ref"} All slides were double scored in a blinded fashion (KV,WM). A third observer (DC) was consulted if consensus could not be reached. The tissue slide with the highest stroma percentage was decisive in cases where multiple slides were available per patient. Stromal areas suspected of postbiopsy effects were excluded from TSR assessment.

The TSR assessment on tumor tissue of patients included in the ONCOPOOL study was assessed using visual microscopy on conventional H&E slides.[14](#ijc32857-bib-0014){ref-type="ref"}

The TSR was scored by the method of Mesker *et al*. in both cohorts.[7](#ijc32857-bib-0007){ref-type="ref"} A percentage of ≤50% stroma was categorized as stroma‐low and \>50% stroma was categorized as stroma‐high (Supporting Information Fig. [S1](#ijc32857-supitem-0001){ref-type="supplementary-material"}).

Statistical analyses {#ijc32857-sec-0007}
--------------------

Statistical analyses were performed using IBM SPSS statistics (version 23 for Windows). The recurrence‐free survival (RFS), the primary endpoint, was defined as the time between the date of diagnosis and local, regional or distant recurrence. Patients who died without a recurrence were censored. Breast cancer‐specific survival (BCSS), the secondary endpoint in the Nottingham Breast Cancer series, was defined as the time from date of diagnosis and breast cancer‐specific death. The BCSS was not available for the ONCOPOOL study. Therefore, in this cohort, the overall survival (OS) was used as the second endpoint. The OS was defined as the time from diagnosis to death from any cause.

The *X* ^*2*^ test was used to evaluate the difference between categorical variables in stroma‐low and stroma‐high groups. Fisher\'s exact test was performed if less than five patients were included per category and Fisher--Freeman--Halton when the table was larger than 2 × 2. The Kaplan--Meier method and the log‐rank test were performed. Cohen\'s kappa coefficient was used to test interobserver variability.

The Cox regression model was used to perform univariate and multivariate analysis. In the multivariate Cox regression analysis of the Nottingham Breast Cancer series, the TSR and confounders were entered; age at diagnosis (continuous), grade (I, II or III), size (≤2 cm and \>2 cm), histological type (invasive carcinoma of no special type \[NST\], lobular carcinoma, tubular carcinoma and others), ER status (negative or positive), PR status (negative or positive) and human epidermal growth factor receptor 2 (HER2) status (negative or positive). These analyses were also performed with triple‐negative status as a variable instead of ER status, PR status and HER2 status. Also, lymph node status was entered in the multivariate Cox regression in addition to standard confounders as described above, as lymph node status is not a confounder but a clinically important parameter. A *p*‐value \<0.05 was considered as statistically significant. The univariate and multivariate Cox regression analysis of the ONCOPOOL study were also performed as described in the original report of Roeke *et al*., to check reproducibility. For the evaluation of the prognostic value of the TSR for clinically relevant subgroups, the interaction term was introduced in the Cox regression analysis. This was corrected for clinically relevant confounders as described above.

Results {#ijc32857-sec-0009}
=======

Patients {#ijc32857-sec-0010}
--------

### *The Nottingham breast cancer series* {#ijc32857-sec-0011}

A total of 2,385 H&E slides of 1,809 patients were assessed for TSR. The slides of 15 (0.8%) patients were not eligible for TSR scoring due to the poor quality of the tissue. The Cohen\'s kappa coefficient was 0.61 between two observers, which corresponds with a substantial to a good level of agreement. Due to the digital learning curve, slides with an incongruent value were individually assessed by the same observers for a second time (blinded from their first scores). Cohen\'s kappa coefficient in the total cohort increased up to 0.87, which corresponds with an almost perfect level of agreement. The H&E slides of 37 patients were discussed with a third observer. A final agreement for the TSR was reached in all cases. A total of 1,794 patients were suitable for statistical analysis. The median age at the time of diagnosis was 55 years (range 23--70 years), and the median follow‐up period was 11 years (range 0--18 years). Table [1](#ijc32857-tbl-0001){ref-type="table"} provides an overview of patient and tumor characteristics.

###### 

Overview of the stratification of age and tumor characteristics of the patients included in the Nottingham Breast Cancer Series

                                       Stroma‐low   Stroma‐high               
  --------------------------- ------- ------------ ------------- ----- ------ ---------
  *Age (in years)*                                                            
  \<40                          144        71          10.4       73    6.6     0.006
  40 to \<50                    385       151          22.2       234   21.0  
  50 to \<60                    636       247          36.3       389   35.0  
  ≥60                           628       212          31.1       416   37.4  
  Missing                        1         0            0.0        1    0.1   
  *Tumor size (in cm)*                                                        
  ≤2                           1,146      505          74.2       641   57.6   \<0.001
  \>2 to \<5                    625       169          24.8       456   41.0  
  ≥5                            21         6            0.9       15    1.3   
  Missing                        2         1            0.1        1    0.1   
  *Lymph node involvement*                                                    
  No                           1,127      452          66.4       675   60.6    0.015
  Yes                           664       227          33.3       437   39.3  
  Missing                        3         2            0.3        1    0.1   
  *Grade*                                                                     
  I                             279       105          15.4       174   15.6    0.606
  II                            733       272          39.9       461   41.4  
  III                           781       303          44.5       478   42.9  
  Missing                        1         1            0.1        0     0    
  *Histological type*                                                         
  Invasive carcinoma of NST    1,129      450          66.1       679   61.0    0.117
  Lobular carcinoma             155        53           7.8       102   9.2   
  Tubular carcinoma             275        90          13.2       185   16.6  
  Others                        235        88          12.9       147   13.2  
  *ER status*                                                                 
  Negative                      331       151          22.2       180   16.2    0.001
  Positive                     1,463      530          77.8       933   83.8  
  *PR status*                                                                 
  Negative                      708       282          41.4       426   38.3    0.262
  Positive                     1,067      390          57.3       677   60.8  
  Missing                       19         9            1.3       10    0.9   
  *HER2 status*                                                               
  Negative                     1,573      594          87.2       979   88.0    0.645
  Positive                      221        87          12.8       134   12.0  
  *Triple‐negative tumors*                                                    
  No                           1,546      560          82.2       986   88.5    0.001
  Yes                           235       115          16.9       120   10.8  
  Missing                       13         6            0.9        7    0.6   
  *Chemotherapy*                                                              
  No                            699       255          37.4       444   39.9    0.577
  Yes                           292       115          16.9       177   15.9  
  Missing                       803       311          45.7       492   44.2  
  *Hormonal therapy*                                                          
  No                            455       182          26.7       273   24.5    0.112
  Yes                           778       274          40.2       504   45.3  
  Missing                       561       225          33.0       336   30.2  

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NST, no special type; PR, progesterone receptor.

### *The ONCOPOOL study* {#ijc32857-sec-0012}

The ONCOPOOL study included 737 women with breast cancer and was previously analyzed for the prognostic value of the TSR.[14](#ijc32857-bib-0014){ref-type="ref"} The median age at inclusion was 54 (range 23--71 years). The median follow‐up was 12 years (range 0--24 years). Patient, tumor and treatment characteristics are shown in Supporting Information Table [S1](#ijc32857-supitem-0001){ref-type="supplementary-material"}.

The prognostic value of the TSR {#ijc32857-sec-0013}
-------------------------------

In the total study population of the Nottingham Breast Cancer series, 681 (38%) patients were categorized in the stroma‐low group and 1,113 (62%) patients in the stroma‐high group. Table [1](#ijc32857-tbl-0001){ref-type="table"} shows the statistically significant differences between both stroma categories. Age, tumor size, lymph node involvement, ER status and triple‐negative tumors were significantly different between both stromal categories.

The Kaplan--Meier analysis and the log‐rank test for RFS showed a statistically significant different outcome between patients with a stroma‐low and stroma‐high tumor in favor of patients with stroma‐low tumors (Supporting Information Fig. [S2](#ijc32857-supitem-0001){ref-type="supplementary-material"}). The TSR was an independent prognostic parameter in favor of patients with stroma‐low tumors for both RFS and BCSS when adjusted for different sets of confounders (Tables [2](#ijc32857-tbl-0002){ref-type="table"} and [3](#ijc32857-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analysis of the Nottingham Breast Cancer Series calculated by Cox regression analysis

                                      Recurrence‐free survival   Breast cancer‐specific survival                                                                                                    
  --------------------------- ------- -------------------------- --------------------------------- ----------- ------ ------------ ----------- ------ ------------- ----------- ------ ------------ -----------
                                *n*   HR                         95% CI                             *p*‐value  HR     95% CI        *p*‐value  HR     95% CI         *p*‐value  HR     95% CI        *p*‐value
  *Age*                                                                                                                                                                                             
                               1,793  0.99                       1.98--1.00                           0.129    1.00   0.99--1.01      0.680    0.99   0.98--1.00       0.222    1.01   0.99--1.02      0.388
  *Tumor size (in cm)*                                                                                                                                                                              
  ≤2                           1,146                                                                 \<0.001                         \<0.001                          \<0.001                         \<0.001
  \>2                           646   2.17                       1.81--2.61                                    1.73   1.42--2.11               2.41   1.93--3.00                1.70   1.35--2.15   
  *Grade*                                                                                                                                                                                           
  I                             279                                                                  \<0.001                         \<0.001                          \<0.001                         \<0.001
  II                            733   1.52                       1.07--2.15                                    1.24   0.83--1.84               2.96   1.66--5.29                2.32   1.34--4.37   
  III                           781   2.91                       2.09--4.06                                    2.08   1.37--3.15               7.01   4.01--12.28               4.67   2.46--8.88   
  *Histological type*                                                                                                                                                                               
  Invasive carcinoma of NST    1,129                                                                 \<0.001                          0.012                           \<0.001                          0.083
  Lobular carcinoma             155   0.93                       0.67--1.30                                    1.30   0.91--1.85               0.90   0.61--1.32                1.44   0.94--2.19   
  Tubular carcinoma             275   0.53                       0.38--0.72                                    0.98   0.70--1.43               0.34   0.22--0.53                0.93   0.56--1.55   
  Others                        235   1.16                       0.90--1.50                                    1.51   1.16--1.97               0.98   0.72--1.34                1.41   1.02--1.95   
  *ER status*                                                                                                                                                                                       
  Negative                      331                                                                  \<0.001                          0.296                           \<0.001                          0.801
  Positive                     1,463  0.64                       0.52--0.80                                    1.16   0.88--1.54               0.50   0.39--0.63                1.04   0.76--1.43   
  *PR status*                                                                                                                                                                                       
  Negative                      708                                                                  \<0.001                          0.011                           \<0.001                          0.005
  Positive                     1,067  0.61                       0.51--0.73                                    0.74   0.59--0.93               0.50   0.40--0.62                0.67   0.51--0.89   
  *HER2 status*                                                                                                                                                                                     
  Negative                     1,573                                                                 \<0.001                         \<0.001                          \<0.001                          0.002
  Positive                      221   2.09                       1.66--2.64                                    1.70   1.32--2.18               2.27   1.74--2.96                1.56   1.17--2.08   
  *TSR*                                                                                                                                                                                             
  Stroma‐low                    681                                                                  \<0.001                          0.004                           \<0.001                          0.001
  Stroma‐high                  1,113  1.46                       1.19--1.78                                    1.35   1.10--1.66               1.60   1.25--2.04                1.51   1.18--1.95   

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NST, no special type; PR, progesterone receptor; TSR, tumor--stroma ratio.

###### 

Results of the independent prognostic value of the tumor--stroma ratio adjusted for only confounders or confounders combined with triple‐negative status or lymph node status calculated with multivariate Cox regression analysis in the Nottingham Breast Cancer series

                                                 Recurrence‐free survival                  Breast cancer‐specific survival
  ---------------------------------------------- ----------------------------------------- -----------------------------------------
  Confounders                                    HR 1.35, 95% CI 1.10--1.66, *p* = 0.004   HR 1.51, 95% CI 1.18--1.95, *p* = 0.001
  Confounders including triple‐negative status   HR 1.34, 95% CI 1.09--1.64, *p* = 0.006   HR 1.47, 95% CI 1.15--1.90, *p* = 0.002
  Confounders and lymph node status              HR 1.35, 95% CI 1.10--1.66, *p* = 0.004   HR 1.51, 95% CI 1.17--1.94, *p* = 0.002

Since the ONCOPOOL study was updated, the prognostic value of the TSR was evaluated again. The analyses showed that patients with a tumor with a high stromal content had a worse survival, in the total cohort as well as in subgroups. The results from the multivariate Cox regression analysis of the updated database were comparable with those of the original observations; RFS HR 1.35, 95% CI 1.01--1.79, *p* = 0.040 *versus* HR 1.35, 95% CI 1.01--1.81, *p* = 0.046 and OS HR 1.46, 95% CI 1.13--1.88, *p* = 0.003 *versus* HR 1.56, 95% CI 1.18--2.05, *p* = 0.002, respectively (data not shown). When the TSR was adjusted for confounders, the OS showed a statistically significant difference in favor of stroma‐low tumors. The results for the RFS were borderline statically significant (Supporting Information Tables [S2](#ijc32857-supitem-0001){ref-type="supplementary-material"} and [S3](#ijc32857-supitem-0001){ref-type="supplementary-material"}).

TSR stratified by clinically important subgroups {#ijc32857-sec-0014}
------------------------------------------------

In Cox regression analysis, the interaction term was introduced, to evaluate the prognostic effect in different clinically important subgroups.

In the Nottingham Breast Cancer series, the interaction term showed a statistically significant *p*‐value for grade (*p* \< 0.001 and *p* = 0.002) and triple‐negative status (*p* = 0.040 and *p* = 0.026) for RFS and BCSS, respectively. No statistically significant results for RFS and BCSS were observed if stratified for age, tumor size, histology, ER status, PR status, HER2 status and lymph node status. The prognostic value of the TSR calculated by multivariate Cox regression analysis showed the most discriminative effect of the TSR in grade III tumors compared to grade I and grade II tumors, and in triple‐negative tumors compared to nontriple‐negative tumors, for RFS and BCSS (Table [4](#ijc32857-tbl-0004){ref-type="table"}). Kaplan--Meier analysis and log‐rank test for RFS of the TSR stratified by grade and triple‐negative status showed a statistically significant difference between subgroups (Figs. [1](#ijc32857-fig-0001){ref-type="fig"} and [2](#ijc32857-fig-0002){ref-type="fig"}).

###### 

Results of the tumor--stroma ratio stratified by clinically important prognostic parameters in the Nottingham Breast Cancer series and the multivariate Cox regression analysis per clinically relevant subgroups with a statistically significant difference

  TSR stratified by group   Subgroups                   Recurrence‐free survival                   Breast cancer‐specific survival
  ------------------------- --------------------------- ------------------------------------------ ------------------------------------------
  Age                                                   *p =* 0.881                                *p =* 0.874
  Tumor size                                            *p =* 0.422                                *p =* 0.209
  Grade                                                 *p* \< 0.001                               *p =* 0.002
                            Grade I                     HR 1.16, 95% CI 0.58--2.29, *p* = 0.670    HR 6.34, 95% CI 0.81--49.95, *p* = 0.079
                            Grade II                    HR 0.78, 95% CI 0.55--1.10, *p* = 0.152    HR 0.83, 95% CI 0.54--1.30, *p* = 0.422
                            Grade III                   HR 1.89, 95% CI 1.43--2.51, *p* \< 0.001   HR 1.86, 95% CI 1.35--2.57, *p* \< 0.001
  Histological type                                     *p =* 0.684                                *p =* 0.951
  ER status                                             *p =* 0.088                                *p =* 0.101
  PR status                                             *p =* 0.861                                *p =* 0.532
  HER2 status                                           *p =* 0.205                                *p =* 0.851
  Triple‐negative status                                *p =* 0.040                                *p =* 0.026
                            Nontriple‐negative status   HR 1.21, 95% CI 0.97--1.51, *p* = 0.095    HR 1.27, 95% CI 0.96--1.67, *p* = 0.092
                            Triple‐negative status      HR 1.86, 95% CI 1.10--3.14, *p* = 0.020    HR 2.24, 95% CI 1.24--4.07, *p* = 0.008
  Lymph node status                                     *p =* 0.995                                *p =* 0.432

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.

![Kaplan--Meier analysis for recurrence‐free survival of patients included in the Nottingham Breast Cancer Series stratified by tumor--stroma ratio combined with grade. \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](IJC-146-2296-g001){#ijc32857-fig-0001}

![Kaplan--Meier analysis for recurrence‐free survival of patients included in the Nottingham Breast Cancer Series stratified by tumor--stroma ratio combined with triple‐negative status. \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](IJC-146-2296-g002){#ijc32857-fig-0002}

The ONCOPOOL study was used to validate the survival effects in grade III tumors and triple‐negative tumors. The interaction term for grade (*p* = 0.122) and triple‐negative status (*p* = 0.343) was not significant for RFS. The hazard ratio (HR) of the prognostic effect of the TSR for RFS were most discriminative in grade III tumors compared to grade I and grade II. If stratified by triple‐negative status, the HR of the TSR in nontriple‐negative tumors was lower compared to triple‐negative tumors, but this was not statistically significant. The interaction term was not statistically significant if stratified by age, tumor size, histology, ER status, PR status, HER2 status and lymph node status (Supporting Information Table [S4](#ijc32857-supitem-0001){ref-type="supplementary-material"}).

Discussion {#ijc32857-sec-0015}
==========

In our study, we evaluated the prognostic value of TSR in, to the best of our knowledge, the largest cohort published on the prognostic value of TSR in breast cancer. The number of patients offered the opportunity to perform analyses of clinically relevant subgroups for breast cancer prognostication and treatment.

First, patients with a stroma‐high tumor had a worse prognosis compared to patients with a stroma‐low tumor. Second, the results of the Nottingham Breast Cancer series showed that the prognostic effect of the TSR was most discriminative in grade III tumors, compared to grade I and grade II tumors, and in triple‐negative tumors, compared to nontriple‐negative tumors. In the ONCOPOOL study, the HRs and confidence intervals of the TSR stratified by grade and triple‐negative status were comparable with the Nottingham Breast Cancer series. The interaction term showed no statistically significant effect for RFS if stratified by grade or triple‐negative status. A possible explanation of the lack of statistical significance is the moderate number of events.

Third, the prognostic effect of the TSR was not modified by age, tumor size, histology, ER status, PR status, HER2 status and lymph node status. This means that the prognostic value of the TSR in these clinically relevant subgroups does not differ from the prognostic value of the total cohort.

No former published literature has evaluated the prognostic value of the TSR by introducing the interaction term. Therefore, the results are not completely comparable. However, previous research showed higher HRs for the TSR in patients with triple‐negative tumors as overviewed by Kramer *et al*.[33](#ijc32857-bib-0033){ref-type="ref"} The effect of the TSR stratified by grade has not been previously described.

The next step toward the clinical implementation of the TSR is to investigate the discriminating prognostic value of the TSR additional to the commonly used online PREDICT tool, which helps oncologists and patients in a shared decision toward personalized therapy.[37](#ijc32857-bib-0037){ref-type="ref"}, [38](#ijc32857-bib-0038){ref-type="ref"} Therefore, retrospective data will be analyzed and a prospective study such as the UNITED (Uniform Noting for International application of the TSRs as Easy Diagnostic Tool) study needs to be performed.[39](#ijc32857-bib-0039){ref-type="ref"} The UNITED study is a prospective international multicenter study initiated by our research group. The study aim is to validate and prepare the TSR for implementation in standard clinical care in patients with colon cancer. Implementation of TSR assessment in standard clinical care has advantages compared to other potential biomarkers as this method is easy to perform, takes less than 2 min and requires no additional costs. Therefore, a comparable study for breast cancer would be desirable in the next step toward clinical implementation. Inter‐observer and intra‐observer reliability of the TSR assessment on digital slides in colon cancer is also evaluated in the UNITED study. The TSR assessment is explained to pathologists and residents *via* e‐learning and test sets.

The Nottingham Breast Cancer series is the first study in which the TSR is digitally assessed on breast cancer tissue by the method of Mesker *et al*.[7](#ijc32857-bib-0007){ref-type="ref"} For the digital assessment, a field of 3.1 mm^2^ was used for final TSR scoring, which corresponds with conventional light microscopy used in our previous research. Van Pelt *et al*. described that the diameters of the different conventional light microscopes are between 2.54 and 3.80 mm^2^. However, this has not led to any major differences in the final score.[36](#ijc32857-bib-0036){ref-type="ref"} One hundred percent of the slides were double scored in a blinded fashion by two observers (KV,WM), instead of the customary 30% double scoring, because of the possible learning curve of scoring digitally for the first time. The Cohen\'s kappa coefficient increased from 0.61 at first assessment to 0.87 in the second assessment of the slides with an incongruent value for the first time. In our opinion, observers who perform digital TSR assessment for the first time need to be aware of a learning curve. If this stage is passed, the TSR scoring on digital slides seems to be reliable and gives, therefore, a good perspective for further digital assessment.

Furthermore, the intratumoral stroma contains valuable prognostic information and may, therefore, be an important source for the development of new stroma based therapeutic agents. A major component of the tumor‐associated stroma and therefore a promising therapeutic target are cancer‐associated fibroblasts (CAFs). At the moment, CAFs are still difficult to target due to the lack of specific cell surface targets, as they are heterogeneous in phenotype and function. An important recent finding is the identification of CD10 and GPR77 as surface markers on CAFs in breast cancer. CD10^+^GPR77^+^ CAFs are predictive for response to chemotherapy and patient survival, particularly in breast tumors with a high grade.[40](#ijc32857-bib-0040){ref-type="ref"} The authors showed that the disease‐free survival of breast cancer patients with a high CD10^+^GPR77^+^ CAF infiltration was significantly shorter. The disease‐free survival of patients with grade I and Grade II tumors was independent of CD10^+^GPR77^+^ CAF infiltration.[6](#ijc32857-bib-0006){ref-type="ref"} These results are interesting as we found that the prognostic value of TSR is most discriminative in grade III tumors compared to grade I and grade II tumors. Whether CAF subtypes differ between stroma‐low and stroma‐high tumors is not known at this moment and requires further research.

Moreover, Ahn et al.[41](#ijc32857-bib-0041){ref-type="ref"} concluded that, especially in patients with grade III tumors, the dominant stroma type was an independent risk factor for disease‐free survival in favor of patients with lymphocyte dominant stroma. Therefore, evaluation of the stromal composition would be interesting, for instance by dividing the stromal compartment in dominant stroma type; collagen, fibroblast or lymphocyte.

Advantages of our study are the large cohort size and long follow‐up period. A limitation of our study is the time period in which patients are included and as a consequence the changes in treatment modalities. In the studied patient groups, proportionally less patients received hormonal therapy than in current treatments. However, previously published research, including the ONCOPOOL study, showed that the TSR was of prognostic value in patients with hormone receptor‐positive tumors who received hormonal therapy.[9](#ijc32857-bib-0009){ref-type="ref"}, [14](#ijc32857-bib-0014){ref-type="ref"} This may suggest that the prognostic value of the TSR can be translated into current hormonal treatment strategies. Also, the introduction of Trastuzumab has positively influenced the clinical outcome. Therefore, a large, more recent retrospective study, in which the change in treatment modalities and a decent follow‐up period are considered, and/or a prospective cohort study should be performed to validate the TSR in the next step toward clinical implementation.

Conclusions {#ijc32857-sec-0016}
===========

The results showed that the prognostic effect of the TSR is most discriminative in grade III tumors, compared to grade I and grade II tumors, and in triple‐negative tumors, compared to nontriple‐negative tumors. Furthermore, the prognostic value of the TSR was not modified by age, tumor size, histology, ER status, PR status, HER2 status and lymph node status. This makes TSR a potential factor for inclusion to improve risk stratification. Validating the TSR in a prospective study could further improve clinical decision‐making using the PREDICT tool.
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